Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.

Carlos H. Barcenas,Sara A. Hurvitz,Jack A. Di Palma,Ron Bose,Arlene Chan,Amy Jo Chien,Cindy Farrell,Daniel Hunt,Leanne McCulloch,Amy Kupic,Debu Tripathy,Hope S. Rugo

Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial.

2019

Carlos H. Barcenas
Sara A. Hurvitz
Jack A. Di Palma
Ron Bose
Arlene Chan
Amy Jo Chien
Cindy Farrell
Daniel Hunt
Leanne McCulloch
Amy Kupic
Debu Tripathy
Hope S. Rugo

548Background: CONTROL (clinicaltrials.gov: NCT02400476) is an open-label, sequential-cohort, phase II study investigating the effectiveness of prophylaxis or dose escalation in preventing diarrhea...

Keywords:

Breast cancer
Physical therapy
Oncology
Neratinib
Diarrhea
Internal medicine
Tolerability
Medicine
in patient
Phases of clinical research
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations